Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 7.71%36.34B | 13.24%9.21B | 13.59%10.78B | 7.23%8.3B | -3.87%8.06B | -1.13%33.74B | -1.35%8.13B | -1.82%9.49B | -5.31%7.74B | 4.18%8.38B |
Cost of revenue | 4.76%21.7B | 11.59%5.41B | 10.06%6.44B | 4.13%5.04B | -7.04%4.81B | 0.37%20.72B | -2.09%4.85B | -1.08%5.85B | -2.76%4.84B | 7.98%5.17B |
Gross profit | 12.40%14.64B | 15.68%3.8B | 19.29%4.33B | 12.41%3.26B | 1.24%3.25B | -3.42%13.02B | -0.23%3.28B | -2.98%3.63B | -9.28%2.9B | -1.39%3.21B |
Operating expense | 9.38%13.06B | 16.40%3.52B | 11.15%3.49B | 10.54%3.1B | -0.72%2.96B | -0.80%11.94B | 1.13%3.02B | -0.84%3.14B | -6.43%2.8B | 3.09%2.98B |
Operating profit | 45.59%1.58B | 7.22%274.9M | 70.57%849M | 65.36%162.87M | 26.16%295.4M | -25.16%1.09B | -13.96%256.38M | -14.61%497.75M | -51.38%98.49M | -36.50%234.14M |
Net non-operating interest income (expenses) | -35.55%15.36M | 43.68%8.53M | -69.49%1.27M | -34.58%4.57M | -85.39%986K | -62.36%23.83M | -12.80%5.94M | -74.82%4.15M | -67.92%6.99M | -62.96%6.75M |
Non-operating interest income | -35.55%15.36M | 43.68%8.53M | -69.49%1.27M | -34.58%4.57M | -85.39%986K | -62.36%23.83M | -12.80%5.94M | -74.82%4.15M | -67.92%6.99M | -62.96%6.75M |
Net investment income | 43.80%196.02M | 59.71%33.7M | 105.55%4.03M | -31.10%59.94M | -2.47%98.36M | -28.30%136.32M | -78.16%21.1M | -326.50%-72.62M | 227.95%86.99M | 188.74%100.85M |
Gain(Loss) on financial instruments designated as cash flow hedges | -160.00%-18.58M | -73.92%-14.99M | -69.63%19.13M | 322.57%7.86M | -21.09%-30.58M | 299.95%30.96M | 48.42%-8.62M | 11,052.35%62.98M | 168.55%1.86M | -660.27%-25.26M |
Gain(Loss) on derecognition of available-for-sale financial assets | 31.16%220.93M | -11.79%66.9M | -93.48%2.79M | 28.55%86.54M | 468.63%64.69M | 26.69%168.43M | -7.04%75.84M | 204.83%42.82M | -14.85%67.32M | -233.40%-17.55M |
Income from associates and other participating interests | -173.99%-15.25M | -37.77%7.95M | -32.58%-22.84M | 66.36%-964K | -65.21%611K | -120.39%-5.56M | 159.94%12.78M | -3,437.99%-17.23M | -130.20%-2.87M | -86.86%1.76M |
Special income (charges) | 43.62%-142.71M | 55.65%-105.65M | -134.03%-26.24M | 97.41%-60K | -682.55%-10.76M | 59.40%-253.14M | 61.41%-238.23M | -430.92%-11.21M | 48.70%-2.32M | -342.93%-1.38M |
Less:Other special charges | -93.68%1.14M | -99.15%105K | -75.09%494K | -97.41%60K | -64.87%483K | 114.79%18.08M | 426.25%12.41M | -6.11%1.98M | -48.70%2.32M | 342.93%1.38M |
Less:Write off | -39.77%141.57M | -53.26%105.54M | 178.96%25.75M | --0 | --10.28M | -61.78%235.06M | -63.28%225.83M | --9.23M | --0 | --0 |
Other non-operating income (expenses) | -22.71%57.65M | 440.36%34.44M | 73.37%5.89M | -63.16%6.16M | -76.80%11.16M | -74.49%74.59M | -49.32%6.37M | -97.40%3.4M | -13.66%16.73M | -62.95%48.09M |
Income before tax | 50.18%1.9B | 132.44%305.79M | 63.33%833.02M | 19.66%326.92M | 23.74%429.86M | -16.92%1.26B | 198.44%131.55M | -28.97%510.03M | -22.30%273.2M | -40.44%347.4M |
Income tax | 17.48%537.28M | -111.30%-5.46M | 67.13%323.82M | 13.92%109.71M | -8.23%109.21M | -10.00%457.35M | 237.47%48.3M | -22.60%193.75M | -15.31%96.3M | -33.62%119M |
Net income | 68.77%1.36B | 273.82%311.24M | 61.00%509.2M | 22.79%217.21M | 40.39%320.65M | -20.40%804.84M | 184.52%83.26M | -32.38%316.28M | -25.64%176.9M | -43.47%228.4M |
Net income continuous operations | 68.77%1.36B | 273.83%311.24M | 61.00%509.2M | 22.79%217.21M | 40.39%320.65M | -20.40%804.84M | 184.52%83.26M | -32.38%316.28M | -25.64%176.9M | -43.46%228.4M |
Noncontrolling interests | -284.02%-3.36M | 55.71%-163K | -926.94%-2.98M | -92.72%81K | -141.97%-303K | -5.82%1.83M | -24.32%-368K | -78.38%360K | -38.58%1.11M | 158.18%722K |
Net income attributable to the company | 69.57%1.36B | 272.37%311.41M | 62.12%512.18M | 23.52%217.13M | 40.97%320.95M | -20.43%803.02M | 185.15%83.63M | -32.22%315.92M | -25.54%175.79M | -43.82%227.68M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 69.57%1.36B | 272.37%311.41M | 62.12%512.18M | 23.52%217.13M | 40.97%320.95M | -20.43%803.02M | 185.15%83.63M | -32.22%315.92M | -25.54%175.79M | -43.82%227.68M |
Gross dividend payment | ||||||||||
Basic earnings per share | 69.54%97.59 | 272.00%22.32 | 62.15%36.71 | 23.49%15.56 | 40.93%23 | -20.43%57.56 | 185.11%6 | -32.24%22.64 | -25.58%12.6 | -43.82%16.32 |
Diluted earnings per share | 69.54%97.59 | 272.36%22.317 | 62.13%36.7058 | 23.49%15.56 | 40.93%23 | -20.43%57.56 | 185.01%5.9935 | -32.24%22.64 | -25.55%12.6 | -43.82%16.32 |
Dividend per share | 8.33%52 | 16.67%28 | 0 | 0.00%24 | 0 | 0.00%48 | -20.00%24 | 0 | 33.33%24 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |